Business Wire

DNA Script Enables Same-day q/dPCR from Design to Results with Launch of Next-generation SYNTAX Kits at AGBT

6.6.2022 15:00:00 EEST | Business Wire | Press release

Share

Today at the Advances in Genome Biology and Technology (AGBT) Conference, DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, announced the launch of the industry’s first solution to enable same-day turnaround for custom q/dPCR assays with a new generation of kits for the SYNTAX System to print both primers and probes in hours. This announcement comes two days ahead of their AGBT presentation on Wed, June 8, at 2:55pm EDT, where their founders will review recent data showcasing the new applications enabled for the SYNTAX System.

For the first time since the introduction of PCR in 1984, labs will be able to design and print q/dPCR assays, directly on their benchtops, in as little as 8 hours. The combination of increased performance, just 15 minutes of set up, rapid synthesis turnaround and complete workflow control provides labs the best value for custom modified oligos. The new kits are designed to accelerate assay development workflows in genomics, in particular for q/dPCR, NGS, ISH and FISH.

“We see this product launch as a game-changer, enabling SYNTAX customers to be done with their assays before others have even started. More than ever before, science and innovation are in a race for results, whether it is an upcoming scientific publication, a new diagnostic test or even a vaccine. Researchers need to get there faster, and we will help them to get there first,” said DNA Script CEO and co-founder Thomas Ybert, Ph.D. “With an in-house, benchtop SYNTAX System and these new kits, we are enabling our customers to replace a complex synthesis workflow with a single instrument that takes the iterative assay development process from months down to days.”

This latest generation of kits launches several new capabilities on the SYNTAX Platform:

  • Print oligos up to 80 nt in length
  • Synthesize hydrolysis probes and primers in the same run, in as little as 8 hours
  • Print oligos at a higher yield and concentration (≥7 µM and ≥600 pmol)
  • Label probes with fluorophores, quenchers and biotin

DNA Script’s SYNTAX Platform offers researchers dramatic time savings, printing primers and probes in 8 - 12 hours, as well as the best value per assay compared to leading third-party oligo service solutions in the marketplace. Early adopters of the SYNTAX platform have already leveraged on-demand synthesis to eliminate bottlenecks in the development of assays for biothreat detection, assays for rapid-response to viral outbreaks, and novel vaccines and therapies.

“The SYNTAX System is a game changer for preclinical CRO labs like ours. For the biomarker identification and gene expression profiling we do, we spend thousands of dollars a month on primers and probes and end up waiting for them to be synthesized and shipped. Having SYNTAX on site cuts our assay turnaround time, decreases our cost per assay by ~30%, and enables our lab to optimize expression assays more quickly--all of which significantly improves our bottom line," said Jonathan Wray, Managing Partner at DC3 Therapeutics. “The ease of use and excellent service and support from DNA Script enabled us to be up and running with the SYNTAX System in no time.”

As a Bronze sponsor, DNA Script is hosting a hospitality room in the Jade-Lexington Suite throughout the duration of the AGBT Conference, where attendees can see the SYNTAX System in action, demonstrating the speed of synthesizing probes and primers in-house with plug-and-play ease and automation. One-on-one demonstrations can be scheduled in advance.

DNA Script presentations at AGBT include:

  • Podium Presentation: Same-Day Enzymatic DNA Synthesis: Now Print Primers and Labeled Probes Using the SYNTAX System
    Presenters: Ybert and DNA Script CTO and co-founder Xavier Godron, Ph.D.
    Date & Time: Wed, June 8, 2:55 - 3:15 pm EDT
    Location: Main Session - Floridian Salons A-L
  • Poster Presentation (#517): Enzymatic DNA Synthesis (EDS) Allows Rapid Access to Synthetic Oligos to Produce Expression Vectors for SARS-CoV-2 Spike Variants
    Presenters: Benoit Derrien, Ph.D., Application Project Leader, DNA Script
    Date & Time: Tues, June 7, 1:30 - 3:00 pm EDT
    Location: Bonnet Creek Ballroom Salon VII-XII
  • Poster Presentation (#540): Access to Synthetic Oligos Produced by Enzymatic DNA Synthesis (EDS) Accelerated the Development of Candida glabrata Mutants During the COVID-19 Pandemic
    Presenters: Colin Clairet, Ph.D., Post-doctoral Researcher, Institut Pasteur
    Date & Time: Wed, June 8, 4:40 pm - 6:10 pm EDT
    Location: Bonnet Creek Ballroom Salon VII-XII

“Since we released the world’s first commercial access to Enzymatic DNA Synthesis via the SYNTAX Platform in the summer of 2021, we have made a number of improvements to advance benchtop DNA printing,” said Ybert. “Given the many applications, and the urgent need to perform them quickly, in-house DNA printing on demand is becoming one of the most important technologies of the 21st century.”

About DNA Script

Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts in the US
Seismic

Valerie Enes
415-692-6799
valerie@teamseismic.com

DNA Script Contact
Joleen Rau
joleen.rau@dnascript.co
publicrelations@dnascript.co

Press contact in Europe
ALIZE RP

Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 16:58:00 EET | Press release

Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, curated and convened by the Department of Health – Abu Dhabi (DoH) together with Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and Mubadala Bio. Held from 20–22 October, the Summit attracted more than 17,300 visitors from 85 countries. It brought together health leaders, researchers, policymakers, investors and inn

De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 16:58:00 EET | Press release

The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par

Starr Chile Assigned A Rating from AM Best11.11.2026 15:30:00 EET | Press release

Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr

Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 15:22:00 EET | Press release

Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an outcome. End customers for Epinal’s SEB include breathalyzer manufacturers, healthcare, mobile computers & clinical smartphones, handheld bio

Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18 th and 19 th11.11.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Jefferies Global Healthcare Conference on November 18 and 19, 2026 and will participate in a fireside chat on November 18 at 9:00am GMT and a panel on November 19 at 10:30am GMT. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/avibSrFufLKeoLRAEgMxy6/eyqYNaU4UZTBAgMVip4JTx A live audio webcast of the panel will be accessible at the following link: https://event.summitcast.com/view/avibSrFufLKeoLRAEgMxy6/guest_book?session_id=H4EMMyKtX5Gd7TPGHGc3Si A replay of both webcasts will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye